 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...221222223224225226227228229230231...235236» |
- Avastin (bevacizumab) / Roche, RG4733 / Roche
Trial withdrawal, Combination therapy, Metastases: Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 6, 2013
P2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Withdrawn
- Avastin (bevacizumab) / Roche, RG4733 / Roche
Enrollment change, Combination therapy, Metastases: Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 6, 2013
P2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Withdrawn N=98 --> 0
- Trial completion: Salvage mFOLFOX in BTC After Failure of Gemcitabine (clinicaltrials.gov) - Oct 5, 2013
P2, N=30, Completed, Sponsor: Chung-Ang University
N=98 --> 0 Recruiting --> Completed
- ||| dilpacimab (ABT-165) / AbbVie
New P1 trial, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Sep 17, 2013
P1, N=75, Recruiting, Sponsor: AbbVie
- || ipatasertib (RG7440) / Roche
Enrollment change, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 16, 2013
P1, N=120, Recruiting, Sponsor: Genentech
Recruiting --> Completed N=60 --> 120
- | Vectibix (panitumumab) / Amgen
Enrollment change: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only (clinicaltrials.gov) - Sep 16, 2013
P2, N=15, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
N=60 --> 120 N=43 --> 15
- | Vectibix (panitumumab) / Amgen
Enrollment closed: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only (clinicaltrials.gov) - Sep 16, 2013
P2, N=15, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
N=43 --> 15 Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Enrollment closed, IO biomarker: PULSE: Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 12, 2013
P2, N=80, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || New P3 trial: A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment. (clinicaltrials.gov) - Sep 11, 2013
P3, N=309, Recruiting, Sponsor: Instituto do Cancer do Estado de S
- New P2 trial: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Sep 11, 2013
P2, N=40, Recruiting, Sponsor: Chinese University of Hong Kong
- | Enrollment open: A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment. (clinicaltrials.gov) - Sep 9, 2013
P3, N=309, Recruiting, Sponsor: Instituto do Cancer do Estado de S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, dulanermin (AMG 951) / Amgen, Roche
Trial completion, Combination therapy, Metastases: A Study of Dulanermin Administered in Combination With Camptosar (clinicaltrials.gov) - Sep 8, 2013
P1, N=42, Completed, Sponsor: Genentech
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial: Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (clinicaltrials.gov) - Sep 6, 2013
P2, N=14, Recruiting, Sponsor: Western Regional Medical Center
- ||||| gedatolisib (PF-05212384) / Celcuity
New P1/2 trial, Metastases: A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 6, 2013
P1/2, N=180, Recruiting, Sponsor: Pfizer
- ||| Herceptin (trastuzumab) / Roche
Enrollment closed: HerFLOT: Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (clinicaltrials.gov) - Sep 4, 2013
P2, N=53, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| leucovorin calcium / Generic mfg., thioguanine / Generic mfg.
Enrollment closed: Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 4, 2013
P3, N=3054, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial initiation date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Sep 3, 2013
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting Initiation date: Jun 2009 --> May 2013
- ||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Metastases: NAPOLI-1: Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Sep 3, 2013
P3, N=405, Active, not recruiting, Sponsor: Merrimack Pharmaceuticals
Initiation date: Jun 2009 --> May 2013 Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Surgery, Metastases: Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer (clinicaltrials.gov) - Aug 29, 2013
P2, N=23, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment closed, Metastases: Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 28, 2013
P1, N=40, Active, not recruiting, Sponsor: University of Nebraska
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- | Zaltrap (ziv-aflibercept IV) / Sanofi
New P1 trial, Combination therapy, Metastases: A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Aug 27, 2013
P1, N=20, Active, not recruiting, Sponsor: Sanofi
- | leucovorin calcium / Generic mfg.
Enrollment open, Metastases: VELVET: OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 26, 2013
P2, N=49, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: A Study in Second Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 22, 2013
P3, N=1050, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New P2 trial: Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer (clinicaltrials.gov) - Aug 21, 2013
P2, N=41, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||||||| thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 20, 2013
P3, N=120, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment change, Combination therapy, Metastases: A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI (clinicaltrials.gov) - Aug 18, 2013
P2, N=30, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed N=21 --> 30
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P3 trial, Metastases: Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 18, 2013
P3, N=172, Recruiting, Sponsor: Stanford University
- || oxaliplatin / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
New P3 trial, Metastases: ABC06: Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Aug 18, 2013
P3, N=162, Recruiting, Sponsor: Christie Hospital NHS Foundation Trust
- Trial completion, Metastases: Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Aug 18, 2013
P2, N=40, Completed, Sponsor: National Taiwan University Hospital
N=21 --> 30 Active, not recruiting --> Completed
- |||| Vectibix (panitumumab) / Amgen
Trial completion: Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 18, 2013
P2, N=154, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || New P2/3 trial: TOPGEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma (clinicaltrials.gov) - Aug 15, 2013
P2/3, N=752, Recruiting, Sponsor: Australasian Gastro-Intestinal Trials Group
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment open, Metastases: Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 15, 2013
P3, N=172, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial, Surgery: Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis (clinicaltrials.gov) - Aug 14, 2013
P2, N=39, Recruiting, Sponsor: Korea Cancer Center Hospital
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer (clinicaltrials.gov) - Aug 14, 2013
P2, N=39, Recruiting, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 13, 2013
P2, N=22, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Enrollment change, Combination therapy, Metastases: A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (clinicaltrials.gov) - Aug 12, 2013
P2, N=8, Terminated, Sponsor: Austrian Breast & Colorectal Cancer Study Group
Active, not recruiting --> Recruiting N=132 --> 8
- | New P2 trial: A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2013
P2, N=39, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- || Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy, Metastases: Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) (clinicaltrials.gov) - Aug 8, 2013
P1, N=180, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=132 --> 8 Recruiting --> Active, not recruiting
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI (clinicaltrials.gov) - Aug 4, 2013
P2, N=30, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg.
Trial completion, Metastases: Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Jul 31, 2013
P3, N=0, Completed, Sponsor: Cancer Research UK
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Stivarga (regorafenib) / Bayer
New P2 trial, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Jul 30, 2013
P2, N=36, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Avastin (bevacizumab) / Roche
Enrollment open, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Jul 30, 2013
P2, N=43, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy, Metastases: Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor (clinicaltrials.gov) - Jul 30, 2013
P1, N=60, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment change, Metastases: E-DIS: Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer. (clinicaltrials.gov) - Jul 29, 2013
P2, N=106, Recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting N=88 --> 106
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: Clinical trial in patients with metastatic colorectal Cancer to evaluate the response of removable liver metastases after treatment with Cetuximab (Erbitux). Ensayo Cl (EUDRACT) - Jul 29, 2013
P2, N=80, Ongoing, Sponsor: ACROSS: Associaci
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Metastases: PROArCT: Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jul 29, 2013
P2, N=41, Completed, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
N=88 --> 106 Not yet recruiting --> Completed
- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
New P3 trial: STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 25, 2013
P3, N=474, Recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Jul 23, 2013
P1/2, N=44, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Completed N=26 --> 44
- New P2 trial, Combination therapy, Metastases: Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer (clinicaltrials.gov) - Jul 21, 2013
P2, N=30, Not yet recruiting, Sponsor: Bruckner Oncology
- Enrollment open, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Jul 18, 2013
P2, N=32, Recruiting, Sponsor: Massachusetts General Hospital
N=26 --> 44 Not yet recruiting --> Recruiting